Jens Klein

Jens is the Founder and CEO of Insempra with its headquarters in Munich, Germany. Insempra is a synthetic biology company which scales biotechnological processes to build ingredients with significantly less energy requirements and waste produced, while eradicating the need for petrochemical or natural extracted ingredients. The company is bridging the gap between leading R&D-focused organizations and brands/OEMS to scale climate focused innovation. The first products in the market are very successful. Jens was heading AMSilk as CEO before. AMSilk is the world’s first industrial supplier of vegan silk biopolymers. AMSilk has announced collaborations and partnerships with world leading brands like Adidas, OMEGA, Mercedes-Benz and Airbus. Jens was responsible for the divestment of the cosmetics division of AMSilk to specialty chemicals giant Givaudan in 2019 serving btob customers like Natura and The Body Shop. Before joining AMSilk, Jens worked for Evonik Industries. In 2011 Evonik acquired Jens’ last companies nanoresins AG and Hanse Chemie AG. Prior, Jens was a member of the Board of Directors of the investment firm Mulligan BioCapital. Mulligan invested in medical technology, biotech and high-tech enterprises in the US and Europe. Before joining Mulligan, he was with Fresenius AG, Bad Homburg where he headed subsidiaries as CEO or CFO.

Wednesday
May 07
Genes to Giants: Strategic Alliances between SynBio and the Fortune 500
3:30 PM

-

4:15 PM

In this insightful session, explore the dynamic intersection of synthetic biology innovations and major corporations in driving scalable impact in consumer products. A curated panel will delve into nuanced discussions around the practicalities, potentials, and challenges of forging partnerships with Fortune 500 companies. Through a spectrum of success stories and practical lessons, attendees will gain a multifaceted understanding of effective strategies that facilitate these cross-sector collaborations. Emphasis will be placed on navigating the intricate corporate dynamics, providing a roadmap for innovators to align their synthetic biology solutions with the strategic priorities of major corporations. Panelists will also dissect the complexities involved in mainstreaming synthetic biology innovations, providing a rich exploration of the adaptive approaches necessary for impactful and sustainable integration into the consumer products industry.

Conference Pass

2,495

USD

Keynotes & Firesides

Workshops & Breakouts

1:1 Partnering App

Meals & Receptions

Session Recordings

Until Friday April 18th

Full Rate:

$3,495

Other Speakers

Copyright SynBioBeta 2025